Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Adult HBV Vaccination: Overcoming Gaps to Lessen the Burden and Impact of HBV

Listen to expert insights on the burden and impact of HBV infection and strategies to overcome barriers to HBV vaccination.
Robert G. Gish, MD
Released: May 5, 2022

In this episode, learn about the importance of hepatitis B virus (HBV) vaccination in adults. Listen as Robert G. Gish, MD, discusses key data on the burden and impact of HBV infection, and strategies to overcome barriers to HBV vaccination.

Information on this Educational Activity


Robert G. Gish, MD

Professor of Medicine
Loma Linda University
Loma Linda, California
Adjunct Professor of Medicine
Nevada School of Medicine
Las Vega, Nevada
Clinical Professor
University of Nevada Reno School of Medicine
Clinical Professor
University of California Skaggs School of Pharmacy and Pharmaceutical Sciences
San Diego, California
Medical Director

Hepatitis B Foundation
Washington, DC

Robert G. Gish, MD, has disclosed that he has received funds for research support from Gilead Sciences; has received consulting fees from Abbott, AbbVie, Altimunne, Antios, Arrowhead, Dynavax, Eiger, Eisai, Enyo, Fibronostics, Fujifilm/Wako, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, Helios, Hepatx, HepQuant, Intercept, Janssen, Merck, Perspectum, Pfizer, Quest, Sonic Incytes, and Topography Health, and Venatorx; has served on advisory boards for AbbVie, Antios, Dynavax, Enyo, Genentech, Genlantis, Gilead, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer and Prodigy; serves on current clinical trials alliance for Topography Health; and has served on data and safety monitoring boards for Altimmune, Arrowhead, CymaBay, and Durect; serves on speakers bureaus for AbbVie, BMS, Eisai, Genentech, Gilead Sciences, and Intercept; and has stock options with Eiger, Genlantis, HepQuant, AngioCrine, HepaTx.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
VBI Vaccines Inc.

Related Content

Professor Graham Foster shares his approach to the management of hepatitis B in older adults, from Clinical Care Options (CCO)

Graham R. Foster, FRCP, PhD Released: November 18, 2022

Expert selections of important viral hepatitis data from AASLD 2022, including studies of patients with HBV, HDV, and HCV, from Clinical Care Options (CCO)

Nancy Reau, MD Stefan Zeuzem, MD Released: November 16, 2022

Expert summaries of key data in older patients with HBV, from Clinical Care Options (CCO)

Graham R. Foster, FRCP, PhD Nancy Reau, MD Released: November 16, 2022

Patient advocates and healthcare provider discuss barriers to HBV screening and diagnosis among African immigrants in the US and offer insights and practical solutions for how to improve these practices

person default Janet Afoakwah, MPH person default William Amiteye Patricia D. Jones, MD, MSCR Released: November 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings